Project Grant R21NS130261
Award Date
9/1/23
Completion Date
8/31/25
Dollars Obligated
$433K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
The National Institutes of Health (NIH), through the National Institute on Aging (NIA) Aging Research Federal Grant Program (CFDA 93.866), awarded a $2,217,438 Cooperative Agreement to the Trustees of Indiana University (IU Indianapolis) to optimize SHIP1 inhibitors for the treatment of Alzheimer's disease. The project aims to develop SHIP1 inhibitors that can improve microglial responses and promote neuroprotective phenotypes, potentially slowing cognitive decline. IU Indianapolis will...
This $3.38 million project grant from the National Institutes of Health's National Institute on Aging will fund research to repurpose FDA-approved agonists of the HCAR2 receptor as novel therapeutics for Alzheimer's disease. The grantee, Indiana University Iupui, will conduct preclinical studies using the 5XFAD mouse model of Alzheimer's disease to evaluate the therapeutic efficacy and pharmacological targets of the FDA-approved drugs niaspan and dimethyl fumarate in modulating microglial...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $120,734 to Trustees of Indiana University (IU Indianapolis) to investigate the role of the fractalkine axis, a key signaling pathway, in Alzheimer's disease pathology using human induced pluripotent stem cells. The central goal is to leverage human cell models to better understand how a specific genetic variant in the CX3CR1 receptor impacts microglial function and induces...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $817,345 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program to Indiana University. The grant aims to identify and understand the role of environmental stressors in the development of Alzheimer's disease-related dementias (ADRD) and related health inequities across urban and rural populations. The project will recruit 600 high-risk...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $792,074 to Trustees of Indiana University (IU Indianapolis) to conduct research on using siRNA-mediated knockdown of the INPP5D gene to modulate microglial activity for the treatment of Alzheimer's disease. The 5-year project aims to identify and characterize INPP5D transcript variants in mouse models, design and validate self-delivering siRNA oligonucleotides that can efficiently and...
The federal Project Grant award R56AG085396, titled "Targeting P2RX7 Signaling as a Treatment for ADRD", is funded by the National Institute on Aging (CFDA 93.866 - Aging Research) for $792,498. The primary awardee, Trustees of Indiana University (doing business as Indiana University Indianapolis), will conduct research to investigate the role of P2X7 receptors in neuroinflammation and neurodegeneration associated with Alzheimer's disease and related dementias (ADRD). The project...
This $399,345 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research to develop novel computational approaches for identifying genetic biomarkers and staging of Alzheimer's disease progression. The award to Trustees of Indiana University (Indianapolis) aims to 1) identify subject-level, stage-specific disease modules using multi-omic data, and 2) develop subject-specific severity staging models using longitudinal imaging data....
The U.S. National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $3,474,488 Cooperative Agreement to Emory University to develop a small-molecule antagonist of the EP2 receptor as a potential treatment for Alzheimer's disease (AD). The project aims to define the pharmacokinetic and pharmacodynamic relationships of the EP2 antagonist lead candidates on AD pathology markers in the brain, as well as on relevant biomarkers in the blood,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support the development of a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic to treat Alzheimer's disease (AD). The $238,500 award to the University of California, San Diego (UCSD) will fund research to generate a highly effective PMO therapeutic that can...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $706,959 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the University of California, Davis. The 5-year grant, awarded on September 18, 2024, will support research to elucidate the molecular signaling mechanisms that regulate the growth, stabilization, and functional maturation of dendritic spines and their associated synapses during activity-dependent...